0000899243-18-017243.txt : 20180619 0000899243-18-017243.hdr.sgml : 20180619 20180619190614 ACCESSION NUMBER: 0000899243-18-017243 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180619 FILED AS OF DATE: 20180619 DATE AS OF CHANGE: 20180619 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dallas Jayson Donald Alexander CENTRAL INDEX KEY: 0001650322 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 18908339 MAIL ADDRESS: STREET 1: AIMMUNE THERAPEUTICS, INC. STREET 2: 8000 MARINA BOULEVARD, SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-19 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001650322 Dallas Jayson Donald Alexander C/O AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 1 1 0 0 President and CEO Common Stock, $0.0001 par value 2018-06-19 4 A 0 60000 0.00 A 60000 D Stock Option (right to buy) 30.68 2018-06-19 4 A 0 350000 0.00 A 2028-06-19 Common Stock 350000 350000 D These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 19, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ Douglas T. Sheehy, as Attorney-in-Fact for Jayson Donald Alexander Dallas 2018-06-19